|
KMID : 0371320130840050273
|
|
Journal of the Korean Surgical Society
2013 Volume.84 No. 5 p.273 ~ p.280
|
|
|
Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
|
|
Cho Dong-Hui
Lee Se-Kyung
Kim Sang-Min
Choi Min-Young
Jung Seung-Pil
Lee Jeong-Hui
Kim Ji-Young
Koo Min-Young
Bae Soo-Youn
Kim Jung-Han
Kim Jee-Soo
Ho Kil-Won
Lee Jeong-Eon
Nam Seok-Jin
Yang Jung-Hyun
|
|
|
Abstract
|
|
|
|
Purpose : We analyzed the responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (NAC) and NAC combined with neoadjuvant human epidermal growth factor receptor-2 (HER2) targeted therapy (NCHTT). Methods : We retrospectively reviewed 59 patients with HER2 amplified locally advanced breast cancer among patients who were treated surgically after neoadjuvant therapy at Samsung Medical Center between 2005 and 2009. Thirty-one patients received conventional NAC and 28 patients received NCHTT. Pathologic responses were assessed according to response evaluation criteria in solid tumors (RECIST) guidelines. Results : Pathologic complete response (pCR) was achieved in 13 out of 28 patients treated with NCHTT and in 6 out of 31 patients treated with NAC alone (46.4% vs. 19.4%, respectively, P = 0.049). Breast conserving surgery (BCS) was more frequently performed in the NCHTT group than in the NAC only group (71.4% vs. 19.4%, P < 0.001). The 3-year recurrence-free survival (RFS) rate was 100% in the NCHTT group and 76.4% in the NAC group (P = 0.014). Together, NCHTT, type of operation (BCS vs. mastectomy) and pathologic nodal status were significant prognostic factors for RFS in univariate analysis. Conclusion : We found that NCHTT produced higher pCR rates than NAC alone in locally advanced breast cancer.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Neoadjuvant therapy, ErbB-2, Response
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|